Peptide · Vial
Verified recordBPC 157
$9010mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Current batchBPC 004-012
Published result99.2% reported purity
EternaGen / RETA 002-044Peptide · Research use only
Retatrutide
From CA$150CAD
An experimental compound designed to act on three metabolic hormone receptors at the same time.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Retatrutide, clearly explained.
An experimental compound designed to act on three metabolic hormone receptors at the same time.
Overview
Retatrutide has reached phase 3 clinical research for weight and blood-sugar outcomes, but it remains investigational and is not approved for public use. Trial findings apply to the sponsor’s controlled product—not a separately sourced material.
Retatrutide is a single investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. It remains under clinical development and is not an approved public-use medicine as of this review.- Format
- Vial
- Available strengths
- 10mg · 20mg · 30mg
- Batch
- RETA 002-044
- Purity
- 99.2%
Research at a glancePhase 2 and emerging phase 3 human evidence; still investigational
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- Confirm in batch record
- Molecular formula
- Confirm in batch record
- Molecular weight
- Confirm in batch record
- Storage and handling
- Follow the batch-specific conditions included with the product documentation.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- RETA 002-044
- Purity
- 99.2%
Important research-use boundary
Retatrutide remains investigational. FDA states it has not been found safe and effective for any condition and cannot be used in compounding under U.S. federal law; Health Canada lists unauthorized injectable retatrutide among products consumers should not buy or use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Obesity and overweight
Phase 2 and phase 3 programmes study body-weight change and related outcomes under controlled escalation schedules.
Evidence so far: Human randomized trialsQuestion 02
Type 2 diabetes
A 2026 phase 3 trial reported HbA1c and body-weight outcomes over 40 weeks in adults inadequately controlled by diet and exercise.
Evidence so far: Published phase 3 evidenceQuestion 03
Safety and tolerability
Trials report gastrointestinal events and other dose-related observations; longer-term outcomes remain under study.
Evidence so far: Evolving clinical safety databaseProposed mechanism
How researchers are investigating the mechanism.
The molecule combines incretin-receptor signalling with glucagon-receptor activity. Clinical trials assess the net effect on glycaemia, appetite-related outcomes, body weight and safety rather than assuming each receptor contributes independently.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Randomized, double-blind 48-week phase 2 trial in 338 adults with obesity
- What researchers saw
- The publication reported dose-dependent body-weight changes and gastrointestinal adverse events.
- Why that is not the whole story
- Trial results apply to Lilly's investigational material and protocol, not a separately sourced product.
Study 02Randomized, double-blind 40-week phase 3 trial in adults with type 2 diabetes
- What researchers saw
- The 2026 publication reported HbA1c and body-weight outcomes across retatrutide and placebo groups.
- Why that is not the whole story
- Published phase 3 data do not equal regulatory approval or establish safe public access.
Evidence gaps
What remains unknown?
- Regulatory review is not complete, and no public-use retatrutide product has been approved.
- Long-term cardiovascular, pancreatic, gallbladder and other safety questions require the complete development programme and regulatory review.
- FDA states retatrutide cannot be used in compounding under U.S. federal law.
Primary sources
Check the original sources.
- Primary phase 2 studyJastreboff et al. Retatrutide for obesity, randomized phase 2 trial. N Engl J Med. 2023. PMID 37366315.
- Primary phase 3 studyBajaj et al. TRANSCEND-T2D-1 randomized phase 3 trial. Lancet. 2026. PMID 42250575.
- Current regulatory warningU.S. FDA. Concerns with unapproved GLP-1 drugs used for weight loss; retatrutide section. 2026.
Related products
Continue comparing.
Peptide · Vial
Verified recordGHK-CU
From CA$5550mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Current batchGHK 006-031
Published result99.5% reported purity
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity